Teachers Advisors LLC raised its holdings in BioTelemetry Inc (NASDAQ:BEAT) by 14.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 58,802 shares of the medical research company’s stock after acquiring an additional 7,312 shares during the quarter. Teachers Advisors LLC’s holdings in BioTelemetry were worth $1,758,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the business. BlackRock Inc. boosted its stake in BioTelemetry by 7.4% in the fourth quarter. BlackRock Inc. now owns 4,093,837 shares of the medical research company’s stock valued at $122,405,000 after acquiring an additional 281,415 shares during the last quarter. Hood River Capital Management LLC boosted its stake in BioTelemetry by 31.1% in the fourth quarter. Hood River Capital Management LLC now owns 1,190,626 shares of the medical research company’s stock valued at $35,600,000 after acquiring an additional 282,687 shares during the last quarter. Pembroke Management LTD boosted its stake in BioTelemetry by 19.1% in the fourth quarter. Pembroke Management LTD now owns 534,900 shares of the medical research company’s stock valued at $15,993,000 after acquiring an additional 85,600 shares during the last quarter. Allianz Asset Management GmbH boosted its stake in BioTelemetry by 23.1% in the fourth quarter. Allianz Asset Management GmbH now owns 526,211 shares of the medical research company’s stock valued at $15,734,000 after acquiring an additional 98,752 shares during the last quarter. Finally, Rice Hall James & Associates LLC bought a new position in BioTelemetry in the fourth quarter valued at approximately $12,319,000. 87.13% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have issued reports on BEAT shares. BidaskClub raised shares of BioTelemetry from a “sell” rating to a “hold” rating in a research note on Wednesday, December 27th. Zacks Investment Research cut shares of BioTelemetry from a “hold” rating to a “sell” rating in a research note on Wednesday, January 31st. TheStreet cut shares of BioTelemetry from a “b-” rating to a “c” rating in a research note on Tuesday, March 20th. Finally, Dougherty & Co reaffirmed a “buy” rating and issued a $41.00 price objective (up from $40.00) on shares of BioTelemetry in a research note on Friday, February 23rd. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $43.00.
In other news, insider Fred Broadway sold 54,158 shares of BioTelemetry stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $34.17, for a total transaction of $1,850,578.86. Following the transaction, the insider now directly owns 64,880 shares of the company’s stock, valued at $2,216,949.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 8.30% of the company’s stock.
Shares of BEAT stock opened at $34.80 on Wednesday. The company has a market capitalization of $1,125.78, a price-to-earnings ratio of 39.54, a price-to-earnings-growth ratio of 1.70 and a beta of 0.86. BioTelemetry Inc has a 52-week low of $23.30 and a 52-week high of $39.20. The company has a current ratio of 1.77, a quick ratio of 1.66 and a debt-to-equity ratio of 0.80.
BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings results on Thursday, February 22nd. The medical research company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.08. The company had revenue of $91.70 million for the quarter, compared to analysts’ expectations of $88.33 million. BioTelemetry had a negative net margin of 5.56% and a positive return on equity of 14.54%. The business’s quarterly revenue was up 69.8% compared to the same quarter last year. During the same period last year, the firm posted $0.23 earnings per share. equities analysts anticipate that BioTelemetry Inc will post 1.27 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “BioTelemetry Inc (BEAT) Shares Bought by Teachers Advisors LLC” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/18/biotelemetry-inc-beat-shares-bought-by-teachers-advisors-llc.html.
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry Inc (NASDAQ:BEAT).
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.